Acadia Pharmaceuticals | ACAD - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 25.92M 5.03M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Cara Therapeutics -89.64M 128.67M 2025-12
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Cytokinetics USD 34.83M 1.5M 2026-06
Eisai JPY 1.96B 409M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Incyte USD 582K 13K 2026-06
J&J USD 43M 25M 2026-03
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 667M 4M 2026-06
Prothena USD 302.58M 47.32M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12